Table 1. Characteristics of Patients Prescribed PCSK9i, First-Day Approval, and Ultimate Approval Rates.
| Parameters | No. of Patients (% Sample) | Patients Approved Day 1, No. (%) |
Patients Ever Receiving Approval, No. (%) |
|---|---|---|---|
| Overall sample | 45 029 (100) | 9371 (20.8) | 21259 (47.2) |
| Age, y | |||
| <45 | 1702 (3.8) | 251 (14.7) | 469 (27.6) |
| 45-54 | 5239 (11.6) | 814 (15.5) | 1736 (33.1) |
| 55-64 | 12 591 (28.0) | 2084 (16.6) | 4441 (35.3) |
| 65-74 | 16 660 (37.0) | 4041 (24.3) | 9435 (56.6) |
| ≥75 | 8837 (19.6) | 2181 (24.7) | 5178 (58.6) |
| Sex | |||
| Female | 23 065 (51.2) | 4788 (20.8) | 10905 (47.3) |
| Male | 21 964 (48.8) | 4583 (20.9) | 10354 (47.1) |
| Pharmacy | |||
| Retail | 35234 (78.2) | 6173 (17.5) | 14882 (42.2) |
| Institutional | 239 (0.5) | 37 (15.5) | 102 (42.7) |
| Mail-order pharmacy | 255 (0.6) | 199 (78.0) | 218 (85.5) |
| Specialty | 9300 (20.7) | 2962 (31.8) | 6057 (65.1) |
| Clinician | |||
| Cardiologist | 21 767 (48.3) | 4844 (22.3) | 11485 (52.8) |
| General practitioner | 16 593 (36.8) | 3112 (18.8) | 6740 (40.6) |
| Endocrinologist | 2234 (5.0) | 428 (19.2) | 997 (44.6) |
| Other clinician | 4435 (9.8) | 987 (22.3) | 2037 (45.9) |
| PBM | |||
| PBM 1 | 3303 (7.3) | 1118 (33.8) | 2211 (66.9) |
| PBM 2 | 500 (1.1) | 98 (19.6) | 195 (39.0) |
| PBM 3 | 1358 (3.0) | 176 (13.0) | 519 (38.2) |
| PBM 4 | 8196 (18.2) | 1346 (16.4) | 3233 (39.4) |
| PBM 5 | 8540 (19.0) | 1298 (15.2) | 3112 (36.4) |
| PBM 6 | 8054 (17.9) | 1943 (24.1) | 5383 (66.8) |
| PBM 7 | 1062 (2.4) | 170 (16.0) | 478 (45.0) |
| PBM 8 | 8163 (18.1) | 1371 (16.8) | 3632 (44.5) |
| PBM 9 | 2833 (6.3) | 430 (15.2) | 1087 (38.4) |
| PBM 10 | 617 (1.4) | 18 (2.9) | 156 (25.3) |
| Payor | |||
| Commercial | 17 999 (40.0) | 2489 (13.8) | 5111 (28.4) |
| Government | 23 652 (52.5) | 5767 (24.4) | 14236 (60.2) |
| Government and commercial | 2043 (4.5) | 332 (16.3) | 1084 (53.1) |
| Other | 1335 (3.0) | 783 (58.7) | 828 (62.0) |
| Clinical | |||
| Overall clinical subsample | 17,851 | 3688 (20.7) | 8738 (48.9) |
| Any ASCVD | 12 186 (68.3) | 2657 (21.8) | 6362 (52.2) |
| CAD | 10 869 (60.9) | 2359 (21.7) | 5708 (52.5) |
| PAD | 3262 (18.3) | 753 (23.1) | 1780 (54.6) |
| CVD | 4235 (23.7) | 952 (22.5) | 2296 (54.2) |
| Statin | |||
| High intensity | 2071 (11.6) | 425 (20.5) | 1012 (48.9) |
| Low to moderate intensity | 2053 (11.5) | 393 (19.1) | 1001 (48.8) |
| No statin | 13727 (76.9) | 2870 (20.9) | 6725 (49.0) |
| Ezetimibe | |||
| Yes | 1874 (10.5) | 389 (20.8) | 972 (51.9) |
| No | 15 977 (89.5) | 3299 (20.6) | 7766 (48.6) |
| Other LLT | |||
| Yes | 2072 (11.6) | 445 (21.5) | 1054 (50.9) |
| No | 15 779 (88.4) | 3243 (20.6) | 7684 (48.7) |
| Laboratories | |||
| Overall laboratory subsample | 5383 (100.0) | 1089 (20.2) | 2637 (49.0%) |
| <70 | 548 (10.2) | 139 (25.4) | 286 (52.2) |
| 70-99 | 726 (13.5) | 160 (22.0) | 368 (50.7) |
| 100-129 | 1031 (19.2) | 219 (21.2) | 528 (51.2) |
| 130-159 | 1246 (23.1) | 228 (18.3) | 621 (49.8) |
| 160-189 | 941 (17.5) | 174 (18.5) | 435 (46.2) |
| ≥190 | 891 (16.6) | 169 (19.0) | 399 (44.8) |
Abbreviations: ASCVD, atherosclerotic cardiovascular disease; CAD, coronary artery disease; CVD, cardiovascular disease; LLT, lipid-lowering therapy; PAD, peripheral artery disease; PBM, pharmacy benefit manager; PCSK9i, proprotein convertase subtilisin/kexin type 9 inhibitors.